Not Yet Recruiting PHASE2 INTERVENTIONAL 5-arm NCT06606483

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

A 24 Weeks, Multicenter, Randomized, Double-blind, Placebo, Parallel-controlled Phase IIb Trail Comparing the Efficacy and Safety of MDR-001 Tablet Versus Placebo in Subjects With Overweight or Obesity

Sponsor: MindRank AI Ltd

Conditions Obesity Overweight and Obesity

Interventions MDR-001 Placebo

Updated 1 time since 2024 Last updated: Sep 22, 2024 Started: Sep 23, 2024 Primary completion: Jul 30, 2025 Completion: Sep 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Obesity and Overweight and Obesity and is currently actively recruiting participants. MindRank AI Ltd leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MindRank AI Ltd

Data source: MindRank AI Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Chenzhou, China , Daqing, China , Haikou, China , Harbin, China , Hefei, China , Jinan, China , Luoyang, China , Nanyang, China and 9 more locations